Get started
Author

Ott Laius

Observed names: Laius, Ott, O. Laius
ORCID: 0000-0003-3828-1373
Observed ORCID: 0000-0003-3828-1373
OpenAlex ID: A5047417686
Policies for biosimilar uptake in Europe: An overview
2017 · Evelien Moorkens, Arnold G. Vulto, et al. · PLoS ONE · 360
PDF
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
2010 · Jakub Adamski, Brian Godman, et al. · BMC Health Services Research · 255
PDF
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
2018 · Brian Godman, Anna Bucsics, et al. · Frontiers in Public Health · 159
PDF
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications
2010 · Brian Godman, William Shrank, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 153
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications
2014 · Brian Godman, Bjorn Wettermark, et al. · Frontiers in Pharmacology · 129
PDF
Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications
2011 · Brian Godman, William Shrank, et al. · Frontiers in Pharmacology · 113
PDF
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
2018 · Tomasz Bochenek, Vafa Abilova, et al. · Frontiers in Pharmacology · 112
PDF
Personalizing health care: feasibility and future implications
2013 · Brian Godman, Alexander E Finlayson, et al. · BMC Medicine · 102
PDF
Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries
2020 · Brian Godman, Holly McCabe, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 97
PDF
Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
2010 · Brian Godman, William Shrank, et al. · Pharmaceuticals · 93
PDF
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
2013 · Rickard E. Malmström, Brian B. Godman, et al. · Frontiers in Pharmacology · 91
PDF
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
2021 · Brian Godman, Andrew Hill, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 75
PDF
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
2021 · Evelien Moorkens, Brian Godman, et al. · Frontiers in Pharmacology · 72
PDF
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
2016 · Michael Ermisch, Anna Bucsics, et al. · Frontiers in Pharmacology · 54
PDF
Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
2019 · Patricia Vella Bonanno, Anna Bucsics, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 47
PDF
European payer initiatives to reduce prescribing costs through use of generics
2012 · Brian Godman, Bjorn Wettermark, et al. · Generics and Biosimilars Initiative Journal · 47
PDF
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
2017 · Patricia Vella Bonanno, Michael Ermisch, et al. · Frontiers in Pharmacology · 45
PDF
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
2019 · Brian Godman, Andrew Hill, et al. · Generics and Biosimilars Initiative Journal · 44
PDF
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
2014 · Brian Godman, Rickard E. Malmström, et al. · Frontiers in Pharmacology · 42
PDF
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
2021 · Brian Godman, Mainul Haque, et al. · Frontiers in Public Health · 39
PDF
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
2016 · Winnie de Bruijn, Cristina Ibáñez, et al. · Frontiers in Pharmacology · 28
PDF
Correspondencesharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
2010 · Jakub Adamski, Brian Godman, et al. · 25
Valproic acid prescription trends among females of childbearing age in Estonia: A 14-year nationwide prescription database study
2020 · Katrin Kurvits, Ott Laius, et al. · Seizure · 17
PDF
Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
2021 · Brian Godman, Magdalene Wladysiuk, et al. · BioMed Research International · 15
PDF
Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future
2015 · Brian Godman, Michael Wilcock, et al. · Generics and Biosimilars Initiative Journal · 15
PDF
Works count: 72
Citation count: 2,355
H-index: 22
I10-index: 29
Year
Topic
Type